TrialPediatric nephrology (Berlin, Germany)2023

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.

Wesley Hayes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.